Correlation Between Triglyceride Glucose Index and Myocardial Injury Assessed by Cardiac Magnetic Resonance Imaging (CMR) in Patients With STEMI

NCT ID: NCT07261514

Last Updated: 2025-12-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

674 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-01-01

Study Completion Date

2024-05-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This research aim is to investigate the correlation between triglyceride glucose index (TyG index) and myocardial infarct size, microcirculation obstruction (MVO) and intramyocardial hemorrhage (IMH) assessed by cardiac magnetic resonance imaging (CMR) in patients with ST-segment elevation myocardial infarction (STEMI), and to evaluate its value as a potential predictor of myocardial injury.To further determine the influence of TyG index on the prognosis of STEMI patients after PCI.This cohort included 674 patients with STEMI undergoing primary percutaneous coronary intervention (pPCI). Baseline clinical data were collected and cardiac magnetic resonance imaging was performed approximately 7 days after Acute Myocardial Infarction(AMI). Patients were divided into three groups according to the TyG index , namely high TyG index group, medium TyG index group and low TyG index group. Multiple linear regression, Pearson/Spearman correlation analysis and Logistics regression analysis were used to analyze the correlation between TyG index and myocardial infarct size, microcirculation obstruction and intramyocardial hemorrhage.Eventually, we came to the conclusion that the TyG index was independently associated with severity of myocardial injury after STEMI as assessed by CMR. TyG index is not only an independent predictor of microcirculation disturbance in STEMI patients, but also significantly correlated with poor cardiovascular prognosis. is a powerful marker for stratifying risk of adverse cardiovascular events.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

ST Elevation (STEMI) Myocardial Infarction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

low TyG index group

Patients with a TyG index below 1.41 were categorized into the low TyG group.

No interventions assigned to this group

medium TyG index

Patients with a TyG index between 1.41 and 1.96 were categorized into the medium TyG group.

No interventions assigned to this group

high TyG index group

Patients with a TyG index greater than 1.96 were categorized into the high TyG index group.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\) patients meet diagnostic criteria for STEMI-"The priority for these patients is the implementation of reperfusion therapy as soon as possible .In the appropriate clinical context,ST-segment elevation (accessed at the J-point) indicates possible acute coronary artery in the following situations:New ST elevation at the J-point in at least two contiguous leads:·≥ 2.5 mm in men under 40years,≥2mm in males 40 years and older,or ≥1.5mmin women relatively less of age in leads V2-V3,and/or ≥1mm in the other leads (in the absence of left ventricular hypertrophy or left bundle branch block) Post-STEMI reperfusion with PCI, diagnosis and treatment strategy in accordance with current diagnosis and treatment standards and guidelines27" and complete pPCI within 48h-"" diagnostic strategy meets current diagnostic criteria and guidelines;2) KillIP\<3 and consent to CMR examination and follow-up observation, and CMR examination is completed within 7 days after surgery. 3) Monitor baseline blood glucose and baseline triglycerides during admission.

Exclusion Criteria

* Contraindications of CMR examination, such as implantable cardiac pacemaker, claustrophobia, allergy to gadolinium contrast agent or renal insufficiency; meanwhile, patients with Killip IV cardiac function or unstable clinical condition, as well as patients with valve disease, congenital heart disease, pulmonary hypertension, cardiomyopathy history, persistent atrial fibrillation, etc. affecting cardiac structure and function parameters shall be excluded; Patients with a history of myocardial infarction, coronary artery intervention, or coronary artery bypass grafting were also excluded. Patients with severe hematological diseases, infectious diseases, malignant tumors, liver and kidney failure, mental disorders or intellectual disabilities who could not cooperate with examination and follow-up, or poor or missing MRI images were not included in the study.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Beijing Anzhen Hospital

OTHER

Sponsor Role collaborator

Beijing Chao Yang Hospital

OTHER

Sponsor Role collaborator

Second Affiliated Hospital of Nanchang University

OTHER

Sponsor Role collaborator

First People's Hospital of Yulin

OTHER

Sponsor Role collaborator

Wuhan Asia Heart Hospital

OTHER

Sponsor Role collaborator

Zunyi Medical College

OTHER

Sponsor Role collaborator

Chinese PLA General Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Qian geng

Associate Chief Physician

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

geng qian

Role: STUDY_DIRECTOR

Chinese PLA General Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Chinese PLA General Hospital

Beijing, Beijing Municipality, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2025QG-TyG index

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.